Loading…

Trajectory of Congestion Metrics by Ejection Fraction in Patients with Acute Heart Failure (From the Heart Failure Network)

Abstract Differences in the clinical course of congestion by underlying ejection fraction (EF) have not been well-characterized in acute heart failure (AHF). A post-hoc analysis was performed using pooled data from the DOSE-AHF, CARRESS-HF, and ROSE-AHF trials. All patients were admitted for a prima...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of cardiology 2017-07, Vol.120 (1), p.98-105
Main Authors: Ambrosy, Andrew P., MD, Bhatt, Ankeet S., MD, Gallup, Dianne, MS, Anstrom, Kevin J., PhD, Butler, Javed, MD, MPH, MBA, DeVore, Adam D., MD, MHS, Felker, G. Michael, MD, MHS, Fudim, Marat, MD, Greene, Stephen J., MD, Hernandez, Adrian F., MD, MHS, Kelly, Jacob P., MD, MHS, Samsky, Marc D., MD, Mentz, Robert J., MD
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c550t-1abe9ab04298eb8b53d2ca8af8241dc58b6d83d41acb33c450d8db73e2b1e4b43
cites cdi_FETCH-LOGICAL-c550t-1abe9ab04298eb8b53d2ca8af8241dc58b6d83d41acb33c450d8db73e2b1e4b43
container_end_page 105
container_issue 1
container_start_page 98
container_title The American journal of cardiology
container_volume 120
creator Ambrosy, Andrew P., MD
Bhatt, Ankeet S., MD
Gallup, Dianne, MS
Anstrom, Kevin J., PhD
Butler, Javed, MD, MPH, MBA
DeVore, Adam D., MD, MHS
Felker, G. Michael, MD, MHS
Fudim, Marat, MD
Greene, Stephen J., MD
Hernandez, Adrian F., MD, MHS
Kelly, Jacob P., MD, MHS
Samsky, Marc D., MD
Mentz, Robert J., MD
description Abstract Differences in the clinical course of congestion by underlying ejection fraction (EF) have not been well-characterized in acute heart failure (AHF). A post-hoc analysis was performed using pooled data from the DOSE-AHF, CARRESS-HF, and ROSE-AHF trials. All patients were admitted for a primary diagnosis of AHF. Patients were grouped as reduced EF < 40%, borderline 40%< EF 50%. Multivariable Cox regression analysis was used to assess the association between measures of congestion and the composite of unscheduled outpatient visits, rehospitalization, or death. Mean age was 68 + 13 years and 74% were male. Patients with a preserved EF were older, more likely to be female, less likely to have an ischemic etiology of HF, and had a higher prevalence of atrial fibrillation/flutter and chronic obstructive pulmonary disease. Compared to patients with a reduced EF, preserved EF patients had lower NT-proBNP levels at baseline (i.e. reduced: 5998 pg/mL [3009 pg/mL, 11414 pg/mL] vs. borderline: 4420 pg/mL [1740 pg/mL, 8057 pg/mL] vs. preserved: 3272 pg/mL [1687 pg/mL, 6536 pg/mL]) and experienced smaller changes during hospitalization. In general, there were few differences between EF groups in the clinical course of congestion as measured by signs and symptoms of HF, body weight change, and net fluid loss. After adjusting for potential confounders, a greater improvement in global visual analogue scale was associated with lower risk of unscheduled outpatient visits, rehospitalization, or death at day 60 (Hazard Ratio 0.94 per 10 mm increase, 95% Confidence Interval 0.89-0.995). This relationship did not differ by EF (p-value = 0.54). In conclusion, among patients hospitalized for AHF there were few differences in the in-hospital trajectory or prognostic value of routine markers of congestion by EF.
doi_str_mv 10.1016/j.amjcard.2017.03.249
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5471496</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0002914917306203</els_id><sourcerecordid>1907313675</sourcerecordid><originalsourceid>FETCH-LOGICAL-c550t-1abe9ab04298eb8b53d2ca8af8241dc58b6d83d41acb33c450d8db73e2b1e4b43</originalsourceid><addsrcrecordid>eNqFkk1v1DAQhiMEokvhJ4AscSmHBE_sfF2KqlWXIpUPiXK2bGe26zSJW9tpteLP42iXAnvhZHv8zOuZeZ0kr4FmQKF832Vy6LR0bZZTqDLKspw3T5IF1FWTQgPsabKglOZpA7w5Sl5438UjQFE-T47ymlcNlNUi-XnlZIc6WLcldk2WdrxGH4wdyWcMzmhP1Jacz8QcWzm525iRfJPB4Bg8eTBhQ870FJBcoHSBrKTpJ4fkZOXsQMLmMP4Fw4N1N-9eJs_Wsvf4ar8eJz9W51fLi_Ty68dPy7PLVBcFDSlIhY1UlOdNjapWBWtzLWu5rnMOrS5qVbY1azlIrRjTvKBt3aqKYa4AueLsODnd6d5OasBWx6qd7MWtM4N0W2GlEf_ejGYjru29KHgVh1dGgZO9gLN3U5yPGIzX2PdyRDt5AXVTcuAMIKJvD9DOTm6M7QloaMWAlVURqWJHaWe9d7h-LAaomO0VndjbK2Z7BWUi2hvz3vzdyWPWbz8j8GEHYJznvUEnvI4uaWyNix6K1pr_PnF6oKB7Mxot-xvcov_TjfC5oOL7_MfmLwYVo2VOGfsFAF_Ppw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1907313675</pqid></control><display><type>article</type><title>Trajectory of Congestion Metrics by Ejection Fraction in Patients with Acute Heart Failure (From the Heart Failure Network)</title><source>ScienceDirect Freedom Collection</source><creator>Ambrosy, Andrew P., MD ; Bhatt, Ankeet S., MD ; Gallup, Dianne, MS ; Anstrom, Kevin J., PhD ; Butler, Javed, MD, MPH, MBA ; DeVore, Adam D., MD, MHS ; Felker, G. Michael, MD, MHS ; Fudim, Marat, MD ; Greene, Stephen J., MD ; Hernandez, Adrian F., MD, MHS ; Kelly, Jacob P., MD, MHS ; Samsky, Marc D., MD ; Mentz, Robert J., MD</creator><creatorcontrib>Ambrosy, Andrew P., MD ; Bhatt, Ankeet S., MD ; Gallup, Dianne, MS ; Anstrom, Kevin J., PhD ; Butler, Javed, MD, MPH, MBA ; DeVore, Adam D., MD, MHS ; Felker, G. Michael, MD, MHS ; Fudim, Marat, MD ; Greene, Stephen J., MD ; Hernandez, Adrian F., MD, MHS ; Kelly, Jacob P., MD, MHS ; Samsky, Marc D., MD ; Mentz, Robert J., MD</creatorcontrib><description>Abstract Differences in the clinical course of congestion by underlying ejection fraction (EF) have not been well-characterized in acute heart failure (AHF). A post-hoc analysis was performed using pooled data from the DOSE-AHF, CARRESS-HF, and ROSE-AHF trials. All patients were admitted for a primary diagnosis of AHF. Patients were grouped as reduced EF &lt; 40%, borderline 40%&lt; EF &lt;50%, or preserved EF &gt; 50%. Multivariable Cox regression analysis was used to assess the association between measures of congestion and the composite of unscheduled outpatient visits, rehospitalization, or death. Mean age was 68 + 13 years and 74% were male. Patients with a preserved EF were older, more likely to be female, less likely to have an ischemic etiology of HF, and had a higher prevalence of atrial fibrillation/flutter and chronic obstructive pulmonary disease. Compared to patients with a reduced EF, preserved EF patients had lower NT-proBNP levels at baseline (i.e. reduced: 5998 pg/mL [3009 pg/mL, 11414 pg/mL] vs. borderline: 4420 pg/mL [1740 pg/mL, 8057 pg/mL] vs. preserved: 3272 pg/mL [1687 pg/mL, 6536 pg/mL]) and experienced smaller changes during hospitalization. In general, there were few differences between EF groups in the clinical course of congestion as measured by signs and symptoms of HF, body weight change, and net fluid loss. After adjusting for potential confounders, a greater improvement in global visual analogue scale was associated with lower risk of unscheduled outpatient visits, rehospitalization, or death at day 60 (Hazard Ratio 0.94 per 10 mm increase, 95% Confidence Interval 0.89-0.995). This relationship did not differ by EF (p-value = 0.54). In conclusion, among patients hospitalized for AHF there were few differences in the in-hospital trajectory or prognostic value of routine markers of congestion by EF.</description><identifier>ISSN: 0002-9149</identifier><identifier>EISSN: 1879-1913</identifier><identifier>DOI: 10.1016/j.amjcard.2017.03.249</identifier><identifier>PMID: 28479167</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Acute Disease ; Age ; Aged ; Beta blockers ; Body weight ; Brain natriuretic peptide ; Cardiovascular ; Cause of Death - trends ; Chronic obstructive pulmonary disease ; Clinical trials ; Congestion ; Death ; Diagnosis ; Diuretics ; Double-Blind Method ; Dyspnea ; Edema ; Ejection fraction ; Etiology ; Female ; Fibrillation ; Flutter ; Heart ; Heart diseases ; Heart failure ; Heart Failure - diagnosis ; Heart Failure - mortality ; Heart Failure - physiopathology ; Hospitalization ; Hospitalization - trends ; Humans ; Ischemia ; Kidneys ; Lung diseases ; Male ; Markers ; Medical prognosis ; Middle Aged ; Mortality ; Natriuretic Peptide, Brain - blood ; Obstructive lung disease ; Optimization ; Patients ; Peptide Fragments - blood ; Peptides ; Prognosis ; Prospective Studies ; Regression analysis ; Renal failure ; Risk assessment ; Risk Assessment - methods ; Self evaluation ; Severity of Illness Index ; Signs and symptoms ; Stroke Volume - physiology ; Survival Rate - trends ; Systole ; Trajectories ; United States - epidemiology ; Vibration ; Visual perception ; Xenografts</subject><ispartof>The American journal of cardiology, 2017-07, Vol.120 (1), p.98-105</ispartof><rights>Elsevier Inc.</rights><rights>2017 Elsevier Inc.</rights><rights>Copyright © 2017 Elsevier Inc. All rights reserved.</rights><rights>Copyright Elsevier Sequoia S.A. Jul 1, 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c550t-1abe9ab04298eb8b53d2ca8af8241dc58b6d83d41acb33c450d8db73e2b1e4b43</citedby><cites>FETCH-LOGICAL-c550t-1abe9ab04298eb8b53d2ca8af8241dc58b6d83d41acb33c450d8db73e2b1e4b43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28479167$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ambrosy, Andrew P., MD</creatorcontrib><creatorcontrib>Bhatt, Ankeet S., MD</creatorcontrib><creatorcontrib>Gallup, Dianne, MS</creatorcontrib><creatorcontrib>Anstrom, Kevin J., PhD</creatorcontrib><creatorcontrib>Butler, Javed, MD, MPH, MBA</creatorcontrib><creatorcontrib>DeVore, Adam D., MD, MHS</creatorcontrib><creatorcontrib>Felker, G. Michael, MD, MHS</creatorcontrib><creatorcontrib>Fudim, Marat, MD</creatorcontrib><creatorcontrib>Greene, Stephen J., MD</creatorcontrib><creatorcontrib>Hernandez, Adrian F., MD, MHS</creatorcontrib><creatorcontrib>Kelly, Jacob P., MD, MHS</creatorcontrib><creatorcontrib>Samsky, Marc D., MD</creatorcontrib><creatorcontrib>Mentz, Robert J., MD</creatorcontrib><title>Trajectory of Congestion Metrics by Ejection Fraction in Patients with Acute Heart Failure (From the Heart Failure Network)</title><title>The American journal of cardiology</title><addtitle>Am J Cardiol</addtitle><description>Abstract Differences in the clinical course of congestion by underlying ejection fraction (EF) have not been well-characterized in acute heart failure (AHF). A post-hoc analysis was performed using pooled data from the DOSE-AHF, CARRESS-HF, and ROSE-AHF trials. All patients were admitted for a primary diagnosis of AHF. Patients were grouped as reduced EF &lt; 40%, borderline 40%&lt; EF &lt;50%, or preserved EF &gt; 50%. Multivariable Cox regression analysis was used to assess the association between measures of congestion and the composite of unscheduled outpatient visits, rehospitalization, or death. Mean age was 68 + 13 years and 74% were male. Patients with a preserved EF were older, more likely to be female, less likely to have an ischemic etiology of HF, and had a higher prevalence of atrial fibrillation/flutter and chronic obstructive pulmonary disease. Compared to patients with a reduced EF, preserved EF patients had lower NT-proBNP levels at baseline (i.e. reduced: 5998 pg/mL [3009 pg/mL, 11414 pg/mL] vs. borderline: 4420 pg/mL [1740 pg/mL, 8057 pg/mL] vs. preserved: 3272 pg/mL [1687 pg/mL, 6536 pg/mL]) and experienced smaller changes during hospitalization. In general, there were few differences between EF groups in the clinical course of congestion as measured by signs and symptoms of HF, body weight change, and net fluid loss. After adjusting for potential confounders, a greater improvement in global visual analogue scale was associated with lower risk of unscheduled outpatient visits, rehospitalization, or death at day 60 (Hazard Ratio 0.94 per 10 mm increase, 95% Confidence Interval 0.89-0.995). This relationship did not differ by EF (p-value = 0.54). In conclusion, among patients hospitalized for AHF there were few differences in the in-hospital trajectory or prognostic value of routine markers of congestion by EF.</description><subject>Acute Disease</subject><subject>Age</subject><subject>Aged</subject><subject>Beta blockers</subject><subject>Body weight</subject><subject>Brain natriuretic peptide</subject><subject>Cardiovascular</subject><subject>Cause of Death - trends</subject><subject>Chronic obstructive pulmonary disease</subject><subject>Clinical trials</subject><subject>Congestion</subject><subject>Death</subject><subject>Diagnosis</subject><subject>Diuretics</subject><subject>Double-Blind Method</subject><subject>Dyspnea</subject><subject>Edema</subject><subject>Ejection fraction</subject><subject>Etiology</subject><subject>Female</subject><subject>Fibrillation</subject><subject>Flutter</subject><subject>Heart</subject><subject>Heart diseases</subject><subject>Heart failure</subject><subject>Heart Failure - diagnosis</subject><subject>Heart Failure - mortality</subject><subject>Heart Failure - physiopathology</subject><subject>Hospitalization</subject><subject>Hospitalization - trends</subject><subject>Humans</subject><subject>Ischemia</subject><subject>Kidneys</subject><subject>Lung diseases</subject><subject>Male</subject><subject>Markers</subject><subject>Medical prognosis</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Natriuretic Peptide, Brain - blood</subject><subject>Obstructive lung disease</subject><subject>Optimization</subject><subject>Patients</subject><subject>Peptide Fragments - blood</subject><subject>Peptides</subject><subject>Prognosis</subject><subject>Prospective Studies</subject><subject>Regression analysis</subject><subject>Renal failure</subject><subject>Risk assessment</subject><subject>Risk Assessment - methods</subject><subject>Self evaluation</subject><subject>Severity of Illness Index</subject><subject>Signs and symptoms</subject><subject>Stroke Volume - physiology</subject><subject>Survival Rate - trends</subject><subject>Systole</subject><subject>Trajectories</subject><subject>United States - epidemiology</subject><subject>Vibration</subject><subject>Visual perception</subject><subject>Xenografts</subject><issn>0002-9149</issn><issn>1879-1913</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNqFkk1v1DAQhiMEokvhJ4AscSmHBE_sfF2KqlWXIpUPiXK2bGe26zSJW9tpteLP42iXAnvhZHv8zOuZeZ0kr4FmQKF832Vy6LR0bZZTqDLKspw3T5IF1FWTQgPsabKglOZpA7w5Sl5438UjQFE-T47ymlcNlNUi-XnlZIc6WLcldk2WdrxGH4wdyWcMzmhP1Jacz8QcWzm525iRfJPB4Bg8eTBhQ870FJBcoHSBrKTpJ4fkZOXsQMLmMP4Fw4N1N-9eJs_Wsvf4ar8eJz9W51fLi_Ty68dPy7PLVBcFDSlIhY1UlOdNjapWBWtzLWu5rnMOrS5qVbY1azlIrRjTvKBt3aqKYa4AueLsODnd6d5OasBWx6qd7MWtM4N0W2GlEf_ejGYjru29KHgVh1dGgZO9gLN3U5yPGIzX2PdyRDt5AXVTcuAMIKJvD9DOTm6M7QloaMWAlVURqWJHaWe9d7h-LAaomO0VndjbK2Z7BWUi2hvz3vzdyWPWbz8j8GEHYJznvUEnvI4uaWyNix6K1pr_PnF6oKB7Mxot-xvcov_TjfC5oOL7_MfmLwYVo2VOGfsFAF_Ppw</recordid><startdate>20170701</startdate><enddate>20170701</enddate><creator>Ambrosy, Andrew P., MD</creator><creator>Bhatt, Ankeet S., MD</creator><creator>Gallup, Dianne, MS</creator><creator>Anstrom, Kevin J., PhD</creator><creator>Butler, Javed, MD, MPH, MBA</creator><creator>DeVore, Adam D., MD, MHS</creator><creator>Felker, G. Michael, MD, MHS</creator><creator>Fudim, Marat, MD</creator><creator>Greene, Stephen J., MD</creator><creator>Hernandez, Adrian F., MD, MHS</creator><creator>Kelly, Jacob P., MD, MHS</creator><creator>Samsky, Marc D., MD</creator><creator>Mentz, Robert J., MD</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TS</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M7Z</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20170701</creationdate><title>Trajectory of Congestion Metrics by Ejection Fraction in Patients with Acute Heart Failure (From the Heart Failure Network)</title><author>Ambrosy, Andrew P., MD ; Bhatt, Ankeet S., MD ; Gallup, Dianne, MS ; Anstrom, Kevin J., PhD ; Butler, Javed, MD, MPH, MBA ; DeVore, Adam D., MD, MHS ; Felker, G. Michael, MD, MHS ; Fudim, Marat, MD ; Greene, Stephen J., MD ; Hernandez, Adrian F., MD, MHS ; Kelly, Jacob P., MD, MHS ; Samsky, Marc D., MD ; Mentz, Robert J., MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c550t-1abe9ab04298eb8b53d2ca8af8241dc58b6d83d41acb33c450d8db73e2b1e4b43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Acute Disease</topic><topic>Age</topic><topic>Aged</topic><topic>Beta blockers</topic><topic>Body weight</topic><topic>Brain natriuretic peptide</topic><topic>Cardiovascular</topic><topic>Cause of Death - trends</topic><topic>Chronic obstructive pulmonary disease</topic><topic>Clinical trials</topic><topic>Congestion</topic><topic>Death</topic><topic>Diagnosis</topic><topic>Diuretics</topic><topic>Double-Blind Method</topic><topic>Dyspnea</topic><topic>Edema</topic><topic>Ejection fraction</topic><topic>Etiology</topic><topic>Female</topic><topic>Fibrillation</topic><topic>Flutter</topic><topic>Heart</topic><topic>Heart diseases</topic><topic>Heart failure</topic><topic>Heart Failure - diagnosis</topic><topic>Heart Failure - mortality</topic><topic>Heart Failure - physiopathology</topic><topic>Hospitalization</topic><topic>Hospitalization - trends</topic><topic>Humans</topic><topic>Ischemia</topic><topic>Kidneys</topic><topic>Lung diseases</topic><topic>Male</topic><topic>Markers</topic><topic>Medical prognosis</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Natriuretic Peptide, Brain - blood</topic><topic>Obstructive lung disease</topic><topic>Optimization</topic><topic>Patients</topic><topic>Peptide Fragments - blood</topic><topic>Peptides</topic><topic>Prognosis</topic><topic>Prospective Studies</topic><topic>Regression analysis</topic><topic>Renal failure</topic><topic>Risk assessment</topic><topic>Risk Assessment - methods</topic><topic>Self evaluation</topic><topic>Severity of Illness Index</topic><topic>Signs and symptoms</topic><topic>Stroke Volume - physiology</topic><topic>Survival Rate - trends</topic><topic>Systole</topic><topic>Trajectories</topic><topic>United States - epidemiology</topic><topic>Vibration</topic><topic>Visual perception</topic><topic>Xenografts</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ambrosy, Andrew P., MD</creatorcontrib><creatorcontrib>Bhatt, Ankeet S., MD</creatorcontrib><creatorcontrib>Gallup, Dianne, MS</creatorcontrib><creatorcontrib>Anstrom, Kevin J., PhD</creatorcontrib><creatorcontrib>Butler, Javed, MD, MPH, MBA</creatorcontrib><creatorcontrib>DeVore, Adam D., MD, MHS</creatorcontrib><creatorcontrib>Felker, G. Michael, MD, MHS</creatorcontrib><creatorcontrib>Fudim, Marat, MD</creatorcontrib><creatorcontrib>Greene, Stephen J., MD</creatorcontrib><creatorcontrib>Hernandez, Adrian F., MD, MHS</creatorcontrib><creatorcontrib>Kelly, Jacob P., MD, MHS</creatorcontrib><creatorcontrib>Samsky, Marc D., MD</creatorcontrib><creatorcontrib>Mentz, Robert J., MD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Physical Education Index</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest research library</collection><collection>Biochemistry Abstracts 1</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The American journal of cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ambrosy, Andrew P., MD</au><au>Bhatt, Ankeet S., MD</au><au>Gallup, Dianne, MS</au><au>Anstrom, Kevin J., PhD</au><au>Butler, Javed, MD, MPH, MBA</au><au>DeVore, Adam D., MD, MHS</au><au>Felker, G. Michael, MD, MHS</au><au>Fudim, Marat, MD</au><au>Greene, Stephen J., MD</au><au>Hernandez, Adrian F., MD, MHS</au><au>Kelly, Jacob P., MD, MHS</au><au>Samsky, Marc D., MD</au><au>Mentz, Robert J., MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Trajectory of Congestion Metrics by Ejection Fraction in Patients with Acute Heart Failure (From the Heart Failure Network)</atitle><jtitle>The American journal of cardiology</jtitle><addtitle>Am J Cardiol</addtitle><date>2017-07-01</date><risdate>2017</risdate><volume>120</volume><issue>1</issue><spage>98</spage><epage>105</epage><pages>98-105</pages><issn>0002-9149</issn><eissn>1879-1913</eissn><abstract>Abstract Differences in the clinical course of congestion by underlying ejection fraction (EF) have not been well-characterized in acute heart failure (AHF). A post-hoc analysis was performed using pooled data from the DOSE-AHF, CARRESS-HF, and ROSE-AHF trials. All patients were admitted for a primary diagnosis of AHF. Patients were grouped as reduced EF &lt; 40%, borderline 40%&lt; EF &lt;50%, or preserved EF &gt; 50%. Multivariable Cox regression analysis was used to assess the association between measures of congestion and the composite of unscheduled outpatient visits, rehospitalization, or death. Mean age was 68 + 13 years and 74% were male. Patients with a preserved EF were older, more likely to be female, less likely to have an ischemic etiology of HF, and had a higher prevalence of atrial fibrillation/flutter and chronic obstructive pulmonary disease. Compared to patients with a reduced EF, preserved EF patients had lower NT-proBNP levels at baseline (i.e. reduced: 5998 pg/mL [3009 pg/mL, 11414 pg/mL] vs. borderline: 4420 pg/mL [1740 pg/mL, 8057 pg/mL] vs. preserved: 3272 pg/mL [1687 pg/mL, 6536 pg/mL]) and experienced smaller changes during hospitalization. In general, there were few differences between EF groups in the clinical course of congestion as measured by signs and symptoms of HF, body weight change, and net fluid loss. After adjusting for potential confounders, a greater improvement in global visual analogue scale was associated with lower risk of unscheduled outpatient visits, rehospitalization, or death at day 60 (Hazard Ratio 0.94 per 10 mm increase, 95% Confidence Interval 0.89-0.995). This relationship did not differ by EF (p-value = 0.54). In conclusion, among patients hospitalized for AHF there were few differences in the in-hospital trajectory or prognostic value of routine markers of congestion by EF.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>28479167</pmid><doi>10.1016/j.amjcard.2017.03.249</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0002-9149
ispartof The American journal of cardiology, 2017-07, Vol.120 (1), p.98-105
issn 0002-9149
1879-1913
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5471496
source ScienceDirect Freedom Collection
subjects Acute Disease
Age
Aged
Beta blockers
Body weight
Brain natriuretic peptide
Cardiovascular
Cause of Death - trends
Chronic obstructive pulmonary disease
Clinical trials
Congestion
Death
Diagnosis
Diuretics
Double-Blind Method
Dyspnea
Edema
Ejection fraction
Etiology
Female
Fibrillation
Flutter
Heart
Heart diseases
Heart failure
Heart Failure - diagnosis
Heart Failure - mortality
Heart Failure - physiopathology
Hospitalization
Hospitalization - trends
Humans
Ischemia
Kidneys
Lung diseases
Male
Markers
Medical prognosis
Middle Aged
Mortality
Natriuretic Peptide, Brain - blood
Obstructive lung disease
Optimization
Patients
Peptide Fragments - blood
Peptides
Prognosis
Prospective Studies
Regression analysis
Renal failure
Risk assessment
Risk Assessment - methods
Self evaluation
Severity of Illness Index
Signs and symptoms
Stroke Volume - physiology
Survival Rate - trends
Systole
Trajectories
United States - epidemiology
Vibration
Visual perception
Xenografts
title Trajectory of Congestion Metrics by Ejection Fraction in Patients with Acute Heart Failure (From the Heart Failure Network)
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T07%3A06%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Trajectory%20of%20Congestion%20Metrics%20by%20Ejection%20Fraction%20in%20Patients%20with%20Acute%20Heart%20Failure%20(From%20the%20Heart%20Failure%20Network)&rft.jtitle=The%20American%20journal%20of%20cardiology&rft.au=Ambrosy,%20Andrew%20P.,%20MD&rft.date=2017-07-01&rft.volume=120&rft.issue=1&rft.spage=98&rft.epage=105&rft.pages=98-105&rft.issn=0002-9149&rft.eissn=1879-1913&rft_id=info:doi/10.1016/j.amjcard.2017.03.249&rft_dat=%3Cproquest_pubme%3E1907313675%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c550t-1abe9ab04298eb8b53d2ca8af8241dc58b6d83d41acb33c450d8db73e2b1e4b43%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1907313675&rft_id=info:pmid/28479167&rfr_iscdi=true